

PRESS RELEASE



December 18, 2017, Lund, Sweden

Invitation to Immunovia's telephone conference on Wednesday, the 20th of December, 2017 at 15:00 (CET)

Immunovia invites you to a telephone conference regarding the initiation of PanDIA-1, the world's largest prospective study of the new onset diabetes (NOD) risk group for pancreatic cancer. The telephone conference will take place 15:00 (CET) the 20th of December, 2017.

The presentation, which is expected to last for a maximum one hour, will be held in English. After a short presentation by CEO Mats Grahn, you will have an opportunity to ask questions. Please dial in a few minutes before the presentation begins.

Date: December 20, 2017

Time: 15:00 (CET)

Telephone number for speakers:

SE: +46 856642692

Telephone number for listeners:

SE: +46 856642665

CH: +41 225675548

DE: +49 69222229046

UK: +44 2030089811

You will find an MP3-file at the Immunovia website at Investors/Financial Reports (<http://immunovia.com/investors/financial-reports/>) which will be available two hours after the end of the presentation.

If you have any questions or want to book an interview:

ir@immunovia.com

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in Stockholm and WildecO is the company's Certified Adviser. For more information, please visit www.immunovia.com.

###